Tuesday, March 5, 2013
Apixaban Featured in the New England Journal of Medicine
The FDA approved apixaban in December 2012 with an indication of reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with non-valvular atrial fibrillation in the United States.
The AMPLIFY trial, conducted by Kevin Cannon, MD and his team at PMG Research of Wilmington, was featured in the New England Journal of Medicine on February 23, 2013.
Apixaban is a new treatment option for reducing the risk of stroke.
Thank you and congratulations to the volunteers who contributed to the development of this new medication for stroke prevention through their participation in this clinical research study.
Be sure to click here to read the New England Journal of Medicine article.
Posted by Sara Rowe at 3:13 PM